Identifying genetic diagnoses for neurologic conditions with a considerable hereditary component, such as autism spectrum disorder, intellectual disability, and epilepsy, is critical to providing proper medical management for patients and their families. However, many patients with these conditions are not tested appropriately or receive no genetic testing at all. The current study was designed to characterize the genetic testing practices of the providers most likely to evaluate or order genetic testing for these patients: pediatric neurologists, geneticists, and genetic counselors. Significant variance was present between testing strategies selected by pediatric neurologists and those by geneticists and genetic counselors, supporting the need for updated genetic testing guidelines that are consistent across specialties. Pediatric neurologists also report lower confidence in ordering genetic testing and desire further education regarding genetic testing. Together, these results propose that continued integration of genetics providers, such as genetic counselors, into pediatric neurology clinics may improve utilization of genetic testing while reducing the burden on pediatric neurologists. Many neurologic conditions identified in childhood, such as autism spectrum disorder, epilepsy, and intellectual disability have a significant genetic component. Approximately 1% of children living in the United States have autism spectrum disorder, and more than 10% of those cases are due to an underlying genetic disorder, such as fragile X syndrome or copy number variants. [1] [2] [3] [4] Similarly, 1% of the US population has epilepsy, and up to 3% of these individuals have a genetic form. 5, 6 Intellectual disability is found in approximately 1% to 3% of all individuals, and depending on severity, 25% to 50% of those cases are related to a genetic abnormality.
Many neurologic conditions identified in childhood, such as autism spectrum disorder, epilepsy, and intellectual disability have a significant genetic component. Approximately 1% of children living in the United States have autism spectrum disorder, and more than 10% of those cases are due to an underlying genetic disorder, such as fragile X syndrome or copy number variants. [1] [2] [3] [4] Similarly, 1% of the US population has epilepsy, and up to 3% of these individuals have a genetic form. 5, 6 Intellectual disability is found in approximately 1% to 3% of all individuals, and depending on severity, 25% to 50% of those cases are related to a genetic abnormality. 7 Given the high prevalence of genetic etiologies for many common childhood-onset neurologic conditions, genetic testing offers considerable value to patients with these disorders. This is not only true for diagnostic purposes but also to determine if other specialty evaluations and treatments are indicated or if there are health or reproductive implications for additional family members. For example, patients with autism spectrum disorder related to fragile X syndrome should be screened for cardiac abnormalities and their family members may require evaluation for fragile X syndrome, premature ovarian insufficiency, or other related health concerns. These recommendations differ greatly from those for children with nonsyndromic autism spectrum disorder. 8 As such, children with autism spectrum disorder who do not receive appropriate genetic testing may not have necessary medical treatments and evaluations.
Proper utilization of genetic testing involves not only ordering testing for patients when indicated, but also selecting the appropriate testing strategy for a particular indication. Previous literature suggests many individuals with neurologic conditions that warrant genetic testing do not receive recommended testing. Approximately 68% of children with autism spectrum disorder do not receive any genetic testing despite current recommendations. 9 The 2013 American College of Medical Genetics and Genomics (ACMG) and American Academy of Pediatrics (AAP) guidelines recommend chromosomal microarray and fragile X syndrome analysis for patients with autism spectrum disorder and patients with intellectual disability. [10] [11] [12] However, the Child Neurology Society Guidelines (CNS) recommend karyotyping and fragile X syndrome analysis for patients with autism spectrum disorder (2000) and for patients with intellectual disability (2010). 10, 13 Currently, there are no professional guidelines outlining best genetic testing practices for patients with epilepsy. Discrepancies in recommendations across specialties for these neurologic conditions present an obstacle to patients receiving recommended testing and appropriate medical care.
To address improper utilization of genetic testing for patients with neurologic conditions, it is necessary to gather data about the practices of the providers that most commonly participate in ordering genetic testing for this population. The purpose of this study was to compare the attitudes and practices of pediatric neurologists, medical geneticists, and genetic counselors regarding genetic testing for pediatric patients with neurologic conditions. Through doing so, this study aimed to identify how practitioners differ in their utilization of genetic testing with the goal of informing plans to increase consistent and appropriate genetic testing for children with common neurogenetic conditions.
Methods

Study Design
Board-certified genetic counselors, medical geneticists, and pediatric neurologists that see patients with neurologic conditions at least once per month and have ordered genetic testing within the last 6 months met the inclusion criteria for this cross-sectional study. Participants were contacted electronically, either personally or through the list server of their respective professional organization. Genetic counselors were recruited from the National Society of Genetic Counselors via an initial electronic mail message and a follow-up reminder 3 weeks later, whereas pediatric neurologists were contacted via the Child Neurology Society (CNS) list server through a single electronic mail message. Medical geneticists were contacted by 2 personal electronic mail messages informing them of the option to participate in this study. Responses were collected between September 22, 2017, and December 10, 2017.
Instrumentation
An investigator-designed, nonvalidated electronic questionnaire hosted on Qualtrics, an online survey software platform, was used for all data collection. All participant responses remained anonymous, and no items were mandatory. Additionally, subjects had the option to submit contact information not linked to individual responses to enter themselves in a random drawing for one of 2 available gift cards.
The survey was divided into 4 sections: assessment of genetic testing utilization (11 items), assessment of testing practice for common indications (including intellectual disability, autism spectrum disorder, and epilepsy) (4 items), self-reported knowledge assessment of genetics topics (4 items), and demographic information (5 items). Question types included single choice, visual analog scale, and Likert scales.
Data Analysis
Data were imported into Stata (v.13.0, College Station, TX) for analysis. Categorical variables were described using frequencies and percentages. Continuous variables were not normally distributed and were described using medians and interquartile ranges. Comparison between clinician groups were made using contingency tests (chi-square or Fisher exact) for categorical variables and using Kruskal-Wallis test with a post hoc Dunn test for continuous variables. Comparison of data between groups was evaluated using descriptive analysis. Statistical significance was assumed at a type I error rate of 5%.
Results
Respondent Demographics
In total, 251 respondents who completed the questionnaire met the inclusion criteria ( Figure 1 ). Of those, 51% reported working in their field for 5 or fewer years, though this rate was highest among genetic counselors, at 79% (P < .001). Genetic counselor respondents were also significantly more likely to be female (93%) than geneticists (61%) or pediatric neurologists (48%) (P < .001) ( Table 1) .
Genetic Testing Volume
When asked about genetic testing practices, there was no difference in the number of genetic tests ordered in the past month between genetic counselors (median: 12, interquartile range: 5-20) and geneticists (median: 12, interquartile range: 8-25). However, neurologists reported a significantly lower number of tests ordered (median: 6, interquartile range: 4-10; P < .001 for both). Respondents were also asked about the types of genetic testing that they have ordered in the last 6 months. Neurologists were significantly less likely to order whole exome sequencing (P < .001) compared to geneticists or genetic counselors. Genetic counselors were less likely to order or assist in ordering chromosomal microarray than other respondents (P .001).
Testing Strategies for Common Neurologic Conditions
When respondents were asked to select first-tier testing strategies for hypothetical patients with isolated neurologic conditions like autism spectrum disorder with or without intellectual disability, isolated intellectual disability, and epilepsy, their responses showed appreciable differences across specialties (Table 2) . Though genetic counselor and geneticist responses were not significantly different, they often varied from the plans selected by pediatric neurologists.
Autism spectrum disorder with intellectual disability. Respondents were most likely to select chromosomal microarray and fragile X syndrome analysis for the first line of testing they would offer to a patient with this indication (93% and 84%, respectively). Only 2% of overall respondents selected that they would order no testing for this indication. Neurologists were significantly less likely to order fragile X analysis than genetic counselors (P ¼ .041), less likely to order whole exome sequencing than genetic counselors and geneticists (P ¼ .002), but more likely to order a karyotype for this indication (P ¼ .020). Most respondents (71%) included both tests currently recommended for first-tier testing, chromosome microarray, and Fragile X analysis. Forty-eight percent of all respondents selected only these 2 tests. Of the respondents who selected chromosomal microarray and fragile X analysis for a patient with autism spectrum disorder and intellectual disability, 13.5% also reported that they would also order whole exome sequencing as a first-line test for this patient. Within that same group, 22% reported they would order a karyotype in addition to a chromosomal microarray and fragile X analysis (12% of genetic counselors, 12% of geneticists, and 27% of neurologists overall).
Autism spectrum disorder without intellectual disability (isolated autism spectrum disorder). Chromosomal microarray and fragile X analysis were the most commonly selected tests for the scenario involving individuals with isolated autism spectrum disorder (73% and 51%, respectively). Overall, 17% of respondents indicated they are unsure of what testing to order, or their decision depends on additional information. Twentysix percent of neurologists responded that they would not order any testing for isolated autism spectrum disorder, significantly more than genetic counselors or geneticists (P < .001). Fortynine percent of respondents chose both chromosome microarray and fragile X analysis for a patient with isolated autism spectrum disorder, and 33% selected those 2 tests exclusively.
Epilepsy. The tests most likely to be selected to evaluate epilepsy were panel gene sequencing for related genes and chromosomal microarray (63% and 41%, respectively). Approximately 28% of respondents reported that they were unsure of the testing they would order or would require more information. Pediatric neurologists were significantly more likely to report that they are unsure/require more information (P < .001) and were less likely to order a chromosomal microarray (P < .001) or whole exome sequencing (P ¼ .002) than other respondents. For patients presenting with epilepsy, respondents were most likely to select panel testing alone (27.1%) or panel testing with chromosomal microarray (13.6%) as their first-tier testing plan.
Intellectual disability. Chromosomal microarray and fragile X analysis were the most selected tests for the indication of intellectual disability (88% and 60%, respectively). Sixteen percent of respondents reported uncertainty about what testing they would choose, or that the decision would depend on additional information. In this case, neurologists were more likely to select that they would not order any testing (P ¼ .046), and less likely to choose chromosomal microarray (P ¼ .001), fragile X analysis (P ¼ .007), or whole exome sequencing (P < .001) for patients with intellectual disability. The most common response across all professions was to order a combination of fragile X analysis and chromosomal microarray when presented with a patient with isolated intellectual disability (29.1%).
Perceived Knowledge Assessment
Respondents rated their knowledge of genetics topics (Table 3) . Pediatric neurologists rated themselves significantly lower than geneticists for knowledge of molecular genetics (P < .001) and testing guidelines for genetic neurologic conditions (P ¼ .007) but ranked themselves highest for knowledge of genetic neurologic conditions.
When asked about their confidence on topics related to ordering genetic tests for patients, neurologists reported significantly lower confidence in knowing when to order genetic tests, choosing the most appropriate test for a patient, interpreting test results, explaining test results to patients, and ordering tests to maximize diagnostic power while minimizing cost (P < .001 for all) ( Table 3 ). There was no significant difference between neurologists' and other respondents' self-reported comfort of handling emotions that may arise during a results disclosure. Compared to medical geneticists, genetic counselors reported less confidence in knowing when to order genetic tests (P ¼ .001) and choosing the most appropriate test for a patient (P ¼ .013).
A majority of neurologists (67%-75%) responded that they would significantly benefit from further training on topics related to genetic testing, such as when to order genetic testing, how to interpret test results, counseling patients about genetic testing options, and explaining genetic testing results to patients. (Table 3) . A majority of genetic counselors (73%-88%) and geneticists (73%-91%) responded that they would not benefit from additional training on these subjects.
When respondents were asked the degree to which they feel genetic testing is utilized in child neurology, a majority of respondents reported that they feel it is somewhat or strongly underutilized (Table 4 ). Of the 3 surveyed professions, pediatric neurologists felt most strongly that genetic testing is underutilized in this field.
Discussion
Children with autism spectrum disorder, intellectual disability, or epilepsy warrant a genetics evaluation as part of their workup, yet many patients with these conditions do not receive recommended genetic testing. 9 This study characterized genetic testing processes and practices of pediatric neurologists, geneticists, and genetic counselors in order to examine the utilization of genetic testing for patients with these common pediatric neurologic conditions. The results demonstrate a lack of consistency between the types of clinicians ordering genetic testing for pediatric neurologic conditions and, furthermore, identify areas where additional education and refinement of guidelines relevant to genetic testing for these conditions would be valuable.
There was significant variance in the testing strategies selected for all neurologic conditions listed (autism spectrum disorder with and without intellectual disability, isolated intellectual disability, and epilepsy). For the majority of questions requiring the participants to select a testing plan for an isolated condition, genetic counselors' and geneticists' responses were not significantly different from each other but were significantly different from the neurologists' responses. Pediatric neurologists were more likely to refrain from ordering testing, particularly for patients with isolated autism spectrum disorder or epilepsy. They were also less likely to order Fragile X analysis for patients with autism spectrum disorder and/or intellectual disability and less likely to order chromosome microarrays or gene panels for patients with epilepsy. These data show that genetic testing guidelines, where they exist, are being followed inconsistently both within and across specialties. For example, current recommendations support ordering chromosome microarray and fragile X analysis as first-tier tests for patients with autism spectrum disorder. [10] [11] [12] Although many respondents overall selected a testing plan that exactly matched these recommendations (48% for autism spectrum disorder with intellectual disability, 33% for isolated autism spectrum disorder), a significant number of respondents did not include one or both of these tests in their testing strategy (29% for autism spectrum disorder with intellectual disability, 51% for isolated autism spectrum disorder). Some providers who are selecting testing plans that differ from published guidelines may be acting on new research about genetic testing for neurologic conditions released after the guidelines were published. 14, 15 Others may be referring to outdated information, such as those ordering karyotypes rather than chromosome microarray for patients with autism spectrum disorder or intellectual disability. In addition, cases where providers indicate that they would order testing not recommended by professional guidelines may be examples of improper utilization of genetic testing. Differences in practice could mean that the genetic testing ordered for a patient is determined more by which specialist sees the patient, rather than the patient's diagnosis. The inconsistencies observed in the testing strategies of respondents describe a strong need for updated, collaborative guidelines that are accessible to and agreed on by pediatric neurologists, medical geneticists, and genetic counselors. Pediatric neurologists reported low confidence in their ability to execute the components of correctly ordering genetic testing-similar to what has been previously observed in neurologists. 16 They also reported being receptive to and interested in further education concerning clinical implementation of genetic testing, along with the belief that genetic testing is currently underutilized in neurology. Thus, the population overall identifies themselves as candidates for further education and training with regard to genetic testing in the child neurology practice.
Ordering genetic testing and interpreting genetic testing results is a growing component of the medical management of patients being cared for by pediatric neurologists. As this trend continues, neurology clinics may benefit from the inclusion of more genetic counselors who can assist with the burden of coordinating genetic testing, stay apprised of the rapidly changing field of neurogenetics, and aid in the interpretation and explanation of genetic test results. This would limit the amount of further training that neurologists require to feel comfortable ordering genetic testing for their patients and improve patient care as well as the efficiency of practices.
The comparatively few participating medical geneticists limited the study's statistical power in comparisons involving this population. Additionally, the survey relied on self-reported data, which may not be an accurate representation of a respondent's actual genetic testing practices or knowledge of genetics topics. The survey tool used was not validated and, as such, there is potential for respondents to interpret questions differently than intended. Further, some sections of this survey did not distinguish between respondents who declined to select a genetic testing plan because they did not know what testing is appropriate for any patients with that indication and those respondents who would require more information to choose the most appropriate plan-such as the types of seizures present in the hypothetical patient with epilepsy. Some respondent selections of testing strategies may be restricted by factors beyond their control, such as insurance guidelines and institutional policies. The testing practice they think is most appropriate for a patient may differ from the testing plan they are able to order when limited by those external factors. Future research should investigate methods for improving proper utilization of genetic testing for pediatric neurology patients, including examining the feasibility of incorporating more genetic counselors into pediatric neurology clinics and improving adherence to genetic testing guidelines. Research that investigates the testing practices of genetics and neurology providers via chart review would also add value.
In conclusion, there are considerable inconsistencies in the testing ordered for common pediatric neurologic conditions by pediatric neurologists, genetic counselors, and medical geneticists. This variance in practice can be addressed with collaborative and updated guidelines addressing genetic testing for these conditions and incorporating genetic counselors and other genetics providers into pediatric neurology clinics.
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